Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-the-Completion-of-the-Tender-Offer-for-VectivBio-Shares/default.aspx
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-of-VectivBio/default.aspx
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Announces-FDA-Approval-of-New-Indication-for-LINZESS-linaclotide-for-the-Treatment-of-Functional-Constipation-in-Pediatric-Patients-Ages-6-17-Years-Old/default.aspx
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Enters-into-Definitive-Agreement-to-Acquire-VectivBio-a-Clinical-Stage-Biotech-Company-Pioneering-Novel-Treatments-for-Severe-Rare-Gastrointestinal-Diseases/default.aspx
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-The-JMP-Securities-Life-Sciences-Conference/default.aspx
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Presents-New-Data-on-Potential-of-Linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old-at-Digestive-Disease-Week-2023/default.aspx
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-First-Quarter-2023-Results-Maintains-Full-Year-2023-Financial-Guidance/default.aspx
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-to-Present-New-Data-at-Digestive-Disease-Week-2023-Demonstrating-Potential-of-Linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspx
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2023-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences/default.aspx
